ARYx Therapeutics

Quick facts

Phase 2 pipeline

• ATI-2042
• ATI-5923 · Neurology
  ATI-5923 is a selective inhibitor of phosphodiesterase 9 (PDE9) that increases cyclic GMP signaling in the central nervous system.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• ARYx Therapeutics portfolio CI brief
• ARYx Therapeutics pipeline updates RSS